{"symbol": "RDHL", "name": "RedHill Biopharma Ltd.", "next_earnings_utc": 1590577200, "next_earnings_period_start_date_utc": 1577750400, "next_earnings_period_end_date_utc": 1585612800, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": null, "next_earnings_revenue_consensus": 4378250.0, "next_earnings_eps_num_analysts": null, "next_earnings_eps_consensus": -0.6, "eps_up_revisions": 0, "eps_down_revisions": 2, "revenue_up_revisions": 1, "revenue_down_revisions": 1, "total_analysts": 4, "analysts_sell": 0, "analysts_buy": 2, "analysts_outperform": 2, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "redhillbio.com", "year_founded": 2009, "street_address": "21 Ha\u2019arba\u2019a Street", "city": "Tel Aviv", "state": null, "zipcode": "6473921", "country": "Israel", "phone_number": "972 3 541 3131", "short_description": "RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on the development and commercialization of drugs for gastrointestinal diseases.", "long_description": "RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on the development and commercialization of drugs for gastrointestinal diseases. The company promotes various gastrointestinal drugs, including Movantik for opioid-induced constipation in adults; Talicia for the treatment of Helicobacter pylori bacterial infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its late-stage clinical development programs include RHB-104, which is in Phase 3 study for treating Crohn's disease; RHB-204, with a planned pivotal Phase 3 study for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) that is in first Phase 3 study to treat acute gastroenteritis and gastritis, as well as has completed Phase 2 study for treating irritable bowel syndrome with diarrhea; RHB-106, which is in planned Phase 2/3 studies for bowel preparation; ABC294640 (Yeliva), a SK2 selective inhibitor, which is in Phase 1/2a study for treating cholangiocarcinoma, as well as in Phase 2 study for prostate cancer; and RHB-107 that is in planned pilot study for cholangiocarcinoma, as well as has completed Phase 2 study for gastrointestinal and other solid tumors. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.", "industry_name": "Pharmaceuticals", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 250061222, "total_enterprise": 206004222, "number_of_employees": 155, "outstanding_shares": 35269566, "eps": -1.424751, "diluted_eps": -1.424751, "earnings_from_cont_operations": -42304000, "gross_profit": 4032000, "cash": 47872000, "total_debt": 3815000, "total_revenue": 6291000, "cash_from_operations": -40749000, "net_income": -42304000, "ebitda": -43098000, "year_low_stock_price": 3.26, "year_high_stock_price": 9.12, "stocktwits_watchlist_count": 2905, "image_url": "https://raw.githubusercontent.com/earnbros/earnbros.github.io/master/api/images/companies/RDHL.png"}